Hepatitis E Diagnostic Tests Market Expansion and Emerging Trends 2026–2034

The global Hepatitis E Diagnostic Tests Market is experiencing gradual growth as awareness of hepatitis E increases and healthcare systems place greater emphasis on infectious disease screening, early diagnosis, and disease surveillance. Diagnostic testing plays an important role in identifying hepatitis E infections and supporting appropriate patient management.

According to Fortune Business Insights, the global Hepatitis E Diagnostic Tests Market size was valued at USD 60.70 million in 2025. The market is projected to grow from USD 63.65 million in 2026 to USD 93.08 million by 2034, exhibiting a CAGR of 4.87% during the forecast period.

Why is the Hepatitis E Diagnostic Tests Market Growing?

Increasing awareness regarding viral hepatitis and the importance of early diagnosis is supporting market expansion. Hepatitis E is commonly associated with contaminated water and food, making diagnostic testing particularly important in regions where sanitation and water quality remain concerns.

Healthcare providers, diagnostic laboratories, hospitals, blood banks, and public health institutions are increasing their focus on accurate hepatitis screening.

Hepatitis E diagnostic tests are used in:

• Hospitals

• Diagnostic Laboratories

• Blood Banks

• Public Health Centers

• Infectious Disease Screening

• Clinical Research

• Disease Surveillance

• Outbreak Monitoring

Increasing healthcare investments and improvements in laboratory infrastructure are expected to create further opportunities for diagnostic test manufacturers.

Key Market Trends Shaping Industry Growth

Increasing Adoption of Automated Testing

Healthcare laboratories are increasingly adopting automated immunoassay platforms to improve testing efficiency and handle larger sample volumes.

Automation can reduce manual processes and support consistent testing workflows, making it increasingly relevant for hospitals and diagnostic centers.

Growth of Rapid Diagnostic Testing

Rapid diagnostic technologies are gaining attention because they can provide faster results and improve accessibility in decentralized healthcare settings.

Portable testing systems can be particularly useful in rural areas, emergency settings, and locations where advanced laboratory infrastructure is limited.

Growing Focus on Disease Surveillance

Governments and healthcare organizations are strengthening infectious disease surveillance programs. Greater emphasis on hepatitis monitoring is supporting demand for diagnostic technologies capable of identifying infections efficiently.

Development of Advanced Diagnostic Technologies

Diagnostic companies are focusing on improving sensitivity, specificity, assay stability, and testing convenience. Multiplex diagnostic technologies and digital laboratory systems are also creating new opportunities for the market.

For more market insights, visit the report: https://www.fortunebusinessinsights.com/hepatitis-e-diagnostic-tests-market-116306

Market Segmentation Analysis

ELISA Tests Remain Important

ELISA HEV IgM tests represent an important product segment because of their use in identifying acute hepatitis E infections. Hospitals, reference laboratories, and research institutions utilize immunoassay-based technologies for efficient antibody detection.

The continued modernization of laboratory infrastructure is expected to support demand for ELISA-based testing solutions.

Rapid Diagnostic Tests Expand Accessibility

Rapid diagnostic tests are increasingly important for decentralized and point-of-care testing. Their portability and faster results can improve access to hepatitis E diagnosis in locations where centralized laboratories are unavailable.

Manufacturers are focusing on affordable and easy-to-use testing solutions to address healthcare needs in emerging markets.

Hospitals Represent a Major End-use Segment

Hospitals remain important users of hepatitis E diagnostic technologies because they provide infectious disease diagnosis, emergency care, and laboratory testing services.

Increasing emphasis on early diagnosis and infectious disease management is encouraging hospitals to invest in modern diagnostic infrastructure.

Blood Banks Support Market Demand

Blood banks represent another important application area as healthcare organizations continue strengthening blood safety and infectious disease screening procedures.

Increasing adoption of high-throughput diagnostic technologies can help blood banks process large numbers of samples efficiently.

Regional Insights

North America Holds a Strong Position

North America represents an important market due to advanced healthcare infrastructure, sophisticated laboratory systems, and increasing awareness of infectious diseases. The region accounted for approximately 34% of the market in the available analysis.

The U.S. benefits from established diagnostic laboratories, healthcare networks, and research institutions supporting the development and adoption of hepatitis testing technologies.

Europe Represents a Significant Market

Europe is supported by established healthcare systems and increasing focus on infectious disease surveillance. The region accounted for approximately 29% of the market.

Greater emphasis on blood safety, foodborne infection monitoring, and laboratory quality standards is supporting market opportunities.

Asia Pacific Offers Growth Potential

Asia Pacific accounted for approximately 31% of the market in the available analysis and represents an important growth region.

Improving healthcare infrastructure, increasing disease awareness, and expanding diagnostic accessibility are expected to support regional growth.

Emerging Markets Gain Attention

Latin America, the Middle East, and Africa are gradually strengthening healthcare infrastructure and infectious disease monitoring capabilities. Increasing investment in rural healthcare and rapid diagnostic technologies could create additional opportunities.

Request Sample Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/hepatitis-e-diagnostic-tests-market-116306

Competitive Landscape

The Hepatitis E Diagnostic Tests Market includes diagnostic manufacturers, biotechnology companies, laboratory technology providers, and specialized infectious disease testing companies.

Companies are focusing on:

• ELISA Testing

• Rapid Diagnostics

• Molecular Testing

• Automated Platforms

• Point-of-Care Testing

• Multiplex Diagnostics

• Laboratory Automation

• Product Innovation

• Research and Development

• Strategic Partnerships

Key companies identified in the market include Wantai BioPharm, MP Biomedicals LLP, PerkinElmer, Inc., Dia.Pro Diagnostic Bioprobes srl, ELITechGroup, Primerdesign Ltd., F. Hoffmann-La Roche Ltd., Mikrogen GmbH, Altona Diagnostics, and Fortress Diagnostics.

Future Outlook

The future outlook for the Hepatitis E Diagnostic Tests Market remains favorable as healthcare providers increasingly prioritize early infectious disease detection and improved diagnostic accessibility.

The market is projected to grow from USD 63.65 million in 2026 to USD 93.08 million by 2034, representing a CAGR of 4.87% during the forecast period.

Growing investments in laboratory infrastructure, point-of-care testing, infectious disease surveillance, and diagnostic automation are expected to support market development. Continued innovation in rapid testing and immunoassay technologies may further improve accessibility and strengthen demand through 2034.

Curious About Japan’s Market? Explore the Latest Hepatitis E Diagnostic Tests Market Insights